The Core Facility for Small Animal Imaging (Head: Prof. Dr. rer. nat. V. Rasche) and Department of Nuclear Medicine (Chair: Prof. Dr. Ambros J. Beer, MD) of Ulm University invite applications for the position of a
PhD student (m / w / d) with a background in life sciences (biology, veterinary medicine, molecular medicine)
The University Hospital Ulm and its employees stands for a modern and high quality patient care, excellent university research and medical education focused on the future as well as apprenticeships in attractive professional fields. The requirements for this are qualified and committed employees.
for supporting ongoing research activities in the field of characterizing peptides and particle-peptide combinations as basis for novel imaging probes within the Collaborative Research Center “Pepini” (SFB1279) on “Exploiting the Human Peptidome for Novel Antimicrobial and Anticancer Agents” and the BMBF lighthouse project “QuE-MRT - Revolutionierung der Krebsbildgebung durch Quantentechnologien”.
Background
The Core Facility Small Animal Imaging and the Department of Nuclear Medicine at Ulm University have significant expertise in pre-clinical multi-modality imaging. Their state-of-the-art infrastructure includes a Bruker BioSpin 11.7T Small Animal MRI with up-to-date sequence development software, a Siemens Focus 120 small animal PET system, a fully equipped cyclotron unit, state-of-the-art GMP radiopharmacy labs, and a highly active preclinical biology research group. These facilities are an integral part of several well-funded research consortia, such as CRC1279, the interdisciplinary DFG-funded “MoMAN” consortium, and the BMBF-funded “QuE-MRT” project.
Projects in the CRC 1279 focus on applying novel tools and methodologies to evaluate and optimize the activity, stability, and delivery of the bioactive probes analyzed. We provide in vitro, in ovo, and in vivo studies with small animal PET and MRI to characterize the pharmacokinetics and biodistribution of newly developed compounds.
In the QuE-MRT project we focus on correlating molecular imaging with hyperpolarized MRI probes with PET in the preclinical setting in ovo and in vivo.
Your Tasks
• Characterization, evaluation and optimization of novel imaging
compounds primarily by in vitro, in ovo and in vivo techniques using small
animal imaging with PET, PET/CT and MRI.
• Development of quantitative and reproducible methods for in vivo compound
quantification by combined PET and MRI methods.
We offer
• International Graduate School in Molecular Medicine Ulm (IGradU)
• Highly interdisciplinary working environment
• Qualification will be supported
The position (75% E13 TV-L) is initially limited to 3 years. The desired date of employment is 01.11.2023
You have/are
• A Master’s degree in life sciences with strong background in molecular biology
(e.g. MolMed, Biology, Veterinary Medicine)
• Experience in small animal imaging is preferable, but not mandatory
• Skills in compound labelling and assessment of pharmacokinetics by PET/MRI
are advantageous but not mandatory
• Highly motivated candidate with lively interest in interdisciplinary molecular
imaging
Background
The Core Facility Small Animal Imaging and the Department of Nuclear Medicine at Ulm University have significant expertise in pre-clinical multi-modality imaging. Their state-of-the-art infrastructure includes a Bruker BioSpin 11.7T Small Animal MRI with up-to-date sequence development software, a Siemens Focus 120 small animal PET system, a fully equipped cyclotron unit, state-of-the-art GMP radiopharmacy labs, and a highly active preclinical biology research group. These facilities are an integral part of several well-funded research consortia, such as CRC1279, the interdisciplinary DFG-funded “MoMAN” consortium, and the BMBF-funded “QuE-MRT” project.
Projects in the CRC 1279 focus on applying novel tools and methodologies to evaluate and optimize the activity, stability, and delivery of the bioactive probes analyzed. We provide in vitro, in ovo, and in vivo studies with small animal PET and MRI to characterize the pharmacokinetics and biodistribution of newly developed compounds.
In the QuE-MRT project we focus on correlating molecular imaging with hyperpolarized MRI probes with PET in the preclinical setting in ovo and in vivo.
Your Tasks
• Characterization, evaluation and optimization of novel imaging
compounds primarily by in vitro, in ovo and in vivo techniques using small
animal imaging with PET, PET/CT and MRI.
• Development of quantitative and reproducible methods for in vivo compound
quantification by combined PET and MRI methods.
We offer
• International Graduate School in Molecular Medicine Ulm (IGradU)
• Highly interdisciplinary working environment
• Qualification will be supported
The position (75% E13 TV-L) is initially limited to 3 years. The desired date of employment is 01.11.2023
You have/are
• A Master’s degree in life sciences with strong background in molecular biology
(e.g. MolMed, Biology, Veterinary Medicine)
• Experience in small animal imaging is preferable, but not mandatory
• Skills in compound labelling and assessment of pharmacokinetics by PET/MRI
are advantageous but not mandatory
• Highly motivated candidate with lively interest in interdisciplinary molecular
imaging
Contract: limited
Level of employment: full-time
application deadline: 15.10.2023
